Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TRVI Trevi Therapeutics Inc

0.03 (2.8%)
Last Updated: 09:38:07
Delayed by 15 minutes


Draw Mode:

Volume 9,972
Bid Price 1.09
Ask Price 1.14
News -
Day High 1.14


52 Week Range


Day Low 1.0901
Company Name Stock Ticker Symbol Market Type
Trevi Therapeutics Inc TRVI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 2.8% 1.10 09:38:07
Open Price Low Price High Price Close Price Prev Close
1.10 1.0901 1.14 1.07
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
45 9,972 $ 1.11 $ 11,026 - 0.97 - 3.50
Last Trade Time Type Quantity Stock Price Currency
09:38:06 100 $ 1.10 USD

Trevi Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
68.33M 63.86M - 0 -29.15M -0.46 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Trevi Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No TRVI Message Board. Create One! See More Posts on TRVI Message Board See More Message Board Posts

Historical TRVI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.071.150.981.081,466,0270.032.8%
1 Month1.531.540.971.14764,575-0.43-28.1%
3 Months2.192.370.971.30315,190-1.09-49.77%
6 Months2.202.970.971.82256,704-1.10-50.0%
1 Year2.113.500.972.03216,587-1.01-47.87%
3 Years3.104.68340.462.17388,234-2.00-64.52%
5 Years9.5010.620.462.38271,831-8.40-88.42%

Trevi Therapeutics Description

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.

Your Recent History

Delayed Upgrade Clock